Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.48
-1.14 (-5.06%)
At close: Apr 28, 2026, 4:00 PM EDT
21.49
+0.01 (0.07%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $501.33 million as of April 28, 2026. Its market cap has increased by 287.18% in one year.
Market Cap
501.33M
Enterprise Value
305.10M
1-Year Change
287.18%
Ranking
Category
Stock Price
$21.48
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $501.33M, a decrease of -87.86%. That is a compound annual growth rate of -35.16%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 501.33M | -23.33% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Upstream Bio | 516.45M |
| Zura Bio | 515.20M |
| AgomAb Therapeutics NV | 513.20M |
| Fulcrum Therapeutics | 507.08M |
| MiMedx Group | 499.93M |
| XOMA Royalty | 497.24M |
| Valneva SE | 485.14M |
| ADC Therapeutics | 483.32M |